IntroductionThe prevalence of type 1 diabetes mellitus (T1DM) is set to rise annually with long-term implications on the quality-of-life. Supplementation with vitamins has garnered interest in recent years due to its association with the development of…
BackgroundThe Glasgow Prognostic Score (GPS) is a well-established prognostic indicator that effectively reflects the inflammatory, nutritional, and immune status of cancer patients. GPS has been shown to be associated with survival outcomes in many di…
IntroductionHepatocellular carcinoma (HCC), accounting for 90% of primary liver cancers, is a high-mortality malignancy and the third leading cause of cancer-related deaths globally, with major risk factors like hepatitis B/C, aflatoxin exposure, and o…
ObjectiveAlthough research on the association between pulmonary fibrosis and lung cancer is of great significance, to date, no bibliometric analysis has been conducted on the comorbidity of these two diseases. This study aims to explore the current sta…
BackgroundHepatocellular carcinoma (HCC) is a major global health challenge, with over 50% of patients ineligible for curative treatments at diagnosis. The combination of molecular targeted therapies and immunotherapy has shown promise in improving out…
ObjectiveImmune treatment beyond progression (ITBP) has emerged as a novel therapeutic strategy in oncology. This systematic review and meta-analysis aim to evaluate the efficacy and safety of ITBP in patients with lung cancer, while also identifying c…
ObjectiveThe association of B lymphocytes and B lymphocyte subsets and Parkinson’s disease (PD) is increasingly acknowledged. However, there is inconsistence in the alterations of B lymphocytes or B lymphocyte subsets in peripheral blood of PD patients…
IntroductionPost-thrombotic syndrome (PTS) is a chronic complication of deep vein thrombosis (DVT). Given its impact on vascular health, understanding risk factors for the development of PTS, as well as conditions such as metabolic syndrome that may co…
BackgroundThe clinical application of immune checkpoint blockade (ICB)-based neoadjuvant therapy has been approved in breast cancer since 2021. However, no studies have evaluated its efficacy and safety in randomized and non-randomized settings. Additi…
BackgroundImmune checkpoint inhibitors (ICIs) plus fluorouracil-based chemotherapy (Chemo) have been approved as an initial treatment strategy for metastatic or recurrent human epidermal growth factor receptor 2 (HER2)-negative gastric cancer (GC) or g…
